Log in

Constellation Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:CNST)

$34.03
+1.69 (+5.23 %)
(As of 11/14/2019 06:41 AM ET)
Today's Range
$31.36
Now: $34.03
$34.92
50-Day Range
$6.30
MA: $13.55
$33.74
52-Week Range
$4.01
Now: $34.03
$45.42
Volume646,600 shs
Average Volume816,072 shs
Market Capitalization$878.65 million
P/E RatioN/A
Dividend YieldN/A
Beta5.32
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNST
CUSIP21036U206
Phone617-714-0555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.86 per share

Profitability

Net Income$-59,920,000.00

Miscellaneous

Employees82
Market Cap$878.65 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.


Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals Inc (NASDAQ:CNST) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

What price target have analysts set for CNST?

6 brokers have issued twelve-month target prices for Constellation Pharmaceuticals' stock. Their forecasts range from $35.00 to $50.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $41.67 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

What is the consensus analysts' recommendation for Constellation Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Has Constellation Pharmaceuticals been receiving favorable news coverage?

News headlines about CNST stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Constellation Pharmaceuticals.

Are investors shorting Constellation Pharmaceuticals?

Constellation Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 788,900 shares, an increase of 27.2% from the September 30th total of 620,400 shares. Based on an average daily trading volume, of 311,200 shares, the short-interest ratio is currently 2.5 days. Approximately 14.7% of the shares of the stock are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Biogen (BIIB), Baidu (BIDU), Lam Research (LRCX), Alibaba Group (BABA), Adobe (ADBE), Axsome Therapeutics (AXSM), Corbus Pharmaceuticals (CRBP), Heron Therapeutics (HRTX), ImmunoGen (IMGN) and NVIDIA (NVDA).

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the folowing people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Sr. VP, CFO Treasurer & Sec. (Age 58)
  • Dr. Adrian M. Senderowicz, Sr. VP & Chief Medical Officer (Age 55)
  • Dr. Danny Reinberg Ph.D., Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an IPO on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Constellation Pharmaceuticals' major shareholders?

Constellation Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include P.A.W. Capital Corp (0.62%) and Alps Advisors Inc. (0.20%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

Which institutional investors are selling Constellation Pharmaceuticals stock?

CNST stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia and Patrick Trojer. View Insider Buying and Selling for Constellation Pharmaceuticals.

Which institutional investors are buying Constellation Pharmaceuticals stock?

CNST stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $34.03.

How big of a company is Constellation Pharmaceuticals?

Constellation Pharmaceuticals has a market capitalization of $878.65 million. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]


MarketBeat Community Rating for Constellation Pharmaceuticals (NASDAQ CNST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  158
MarketBeat's community ratings are surveys of what our community members think about Constellation Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel